WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Daniel Cho
Associate
Corporate
Palo Alto
daniel.cho@wsgr.com

D650-849-3320

Download vCard
Open PDF

Daniel Cho is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters.

Prior to joining the firm, Daniel was in-house counsel and an associate at a Palo Alto-based venture capital firm, where he advised the management team on successfully raising the firm's debut fund and worked directly with the general partner at all stages of investments. He also oversaw and managed all aspects of legal operations of the firm, including fund formation/governance, deal executions, and exit transactions.

Experience

Daniel Cho is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters.

Prior to joining the firm, Daniel was in-house counsel and an associate at a Palo Alto-based venture capital firm, where he advised the management team on successfully raising the firm's debut fund and worked directly with the general partner at all stages of investments. He also oversaw and managed all aspects of legal operations of the firm, including fund formation/governance, deal executions, and exit transactions.

Education
  • J.D., University of Washington School of Law
  • B.A., Psychology, University of California, San DiegoCum Laude
Admissions
  • State Bar of California
Credentials
Education
  • J.D., University of Washington School of Law
  • B.A., Psychology, University of California, San DiegoCum Laude
Admissions
  • State Bar of California
Focus Areas
  • Corporate
  • Corporate Governance
  • Emerging Companies and Venture Capital
  • Medical Devices
  • Mergers & Acquisitions
Recent Insights
Client Highlights
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Learn More
Client Highlights
Firm Advises ABL Bio on Strategic Alliance and Equity Investment with Eli Lilly
On November 14, 2025, ABL Bio announced a broad strategic research and development alliance with Eli Lilly and Company, establishing a multi-program collaboration to advance next-generation therapeutics using ABL Bio’s Grabody Platform. Wilson Sonsini Goodrich & Rosati advised ABL Bio on the license, research, and collaboration agreement, which is valued at up to $2.602 billion, including a $40 million upfront payment. Through this partnership, ABL Bio and Lilly will jointly explore and develop multiple therapeutic modalities across a range of disease areas, marking a significant expansion of ABL Bio’s platform-driven global collaborations.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.